 Ajay Major
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2026 | 190 | 3.760 |
Why?
| | Hematologic Neoplasms | 3 | 2025 | 159 | 2.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 15 | 2026 | 1791 | 1.940 |
Why?
| | Multiple Myeloma | 9 | 2024 | 280 | 1.880 |
Why?
| | Hodgkin Disease | 5 | 2025 | 158 | 1.690 |
Why?
| | Neoplasms, Second Primary | 2 | 2026 | 98 | 1.460 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 123 | 1.440 |
Why?
| | Medical Oncology | 5 | 2024 | 316 | 1.370 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 670 | 1.350 |
Why?
| | Neoplasms | 5 | 2025 | 2731 | 1.240 |
Why?
| | Cancer Survivors | 2 | 2026 | 281 | 1.120 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 59 | 1.000 |
Why?
| | Vascular Access Devices | 1 | 2025 | 29 | 0.930 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2162 | 0.900 |
Why?
| | Survivors | 2 | 2026 | 501 | 0.850 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 115 | 0.830 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 358 | 0.820 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 1075 | 0.790 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 451 | 0.780 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 254 | 0.770 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 60 | 0.740 |
Why?
| | Plasma Exchange | 1 | 2021 | 18 | 0.720 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 15 | 0.710 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 133 | 0.690 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 13 | 0.690 |
Why?
| | Cyclophosphamide | 4 | 2024 | 257 | 0.690 |
Why?
| | Quality of Life | 5 | 2025 | 3024 | 0.680 |
Why?
| | Humans | 60 | 2026 | 141284 | 0.680 |
Why?
| | Dexamethasone | 7 | 2024 | 375 | 0.680 |
Why?
| | Lymphoma, B-Cell | 2 | 2022 | 131 | 0.680 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 29 | 0.670 |
Why?
| | Hospice Care | 1 | 2024 | 204 | 0.670 |
Why?
| | Vaccination | 2 | 2021 | 1468 | 0.670 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1035 | 0.640 |
Why?
| | Internship and Residency | 2 | 2021 | 1230 | 0.640 |
Why?
| | Terminal Care | 1 | 2024 | 252 | 0.640 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 53 | 0.600 |
Why?
| | Drug Costs | 1 | 2020 | 114 | 0.590 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 112 | 0.580 |
Why?
| | Internal Medicine | 1 | 2021 | 273 | 0.560 |
Why?
| | Colorectal Neoplasms | 1 | 2026 | 811 | 0.550 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 29 | 0.540 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1282 | 0.540 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 22 | 0.520 |
Why?
| | Etoposide | 3 | 2024 | 163 | 0.510 |
Why?
| | Oncologists | 1 | 2017 | 43 | 0.510 |
Why?
| | Vincristine | 3 | 2024 | 130 | 0.510 |
Why?
| | Neoplasm, Residual | 4 | 2024 | 130 | 0.510 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 169 | 0.500 |
Why?
| | Oligopeptides | 5 | 2024 | 264 | 0.500 |
Why?
| | Immunocompromised Host | 1 | 2018 | 201 | 0.490 |
Why?
| | Mental Health Services | 1 | 2021 | 445 | 0.480 |
Why?
| | Medicare | 2 | 2023 | 802 | 0.470 |
Why?
| | Lymphoma | 3 | 2023 | 228 | 0.470 |
Why?
| | Empathy | 1 | 2017 | 176 | 0.450 |
Why?
| | Doxorubicin | 3 | 2024 | 369 | 0.450 |
Why?
| | Aged | 21 | 2026 | 24836 | 0.440 |
Why?
| | Middle Aged | 21 | 2026 | 34658 | 0.440 |
Why?
| | Mental Health | 1 | 2021 | 756 | 0.430 |
Why?
| | Health Personnel | 1 | 2021 | 727 | 0.430 |
Why?
| | Students, Medical | 2 | 2021 | 370 | 0.420 |
Why?
| | Hematology | 3 | 2024 | 20 | 0.410 |
Why?
| | Rituximab | 3 | 2024 | 204 | 0.410 |
Why?
| | Aged, 80 and over | 11 | 2026 | 7948 | 0.410 |
Why?
| | Adult | 19 | 2026 | 39319 | 0.410 |
Why?
| | Curriculum | 1 | 2020 | 1035 | 0.400 |
Why?
| | Bullying | 1 | 2014 | 44 | 0.400 |
Why?
| | Prognosis | 7 | 2026 | 4080 | 0.400 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1030 | 0.390 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 282 | 0.390 |
Why?
| | Treatment Outcome | 11 | 2026 | 11216 | 0.390 |
Why?
| | Physicians | 1 | 2021 | 930 | 0.370 |
Why?
| | Prednisone | 2 | 2024 | 228 | 0.370 |
Why?
| | Young Adult | 10 | 2026 | 13727 | 0.370 |
Why?
| | Mental Disorders | 1 | 2021 | 1133 | 0.370 |
Why?
| | SEER Program | 2 | 2026 | 219 | 0.370 |
Why?
| | Healthcare Disparities | 1 | 2018 | 674 | 0.360 |
Why?
| | Male | 24 | 2026 | 70140 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 641 | 0.360 |
Why?
| | Pediatrics | 1 | 2020 | 1102 | 0.360 |
Why?
| | Delivery of Health Care | 1 | 2018 | 948 | 0.350 |
Why?
| | Faculty, Medical | 1 | 2014 | 290 | 0.330 |
Why?
| | Education, Medical | 1 | 2014 | 271 | 0.330 |
Why?
| | Skin Neoplasms | 1 | 2017 | 851 | 0.310 |
Why?
| | Female | 22 | 2026 | 75814 | 0.310 |
Why?
| | Public Health Surveillance | 2 | 2020 | 83 | 0.300 |
Why?
| | Information Dissemination | 2 | 2022 | 209 | 0.290 |
Why?
| | Antibodies, Monoclonal | 4 | 2026 | 1456 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 908 | 0.270 |
Why?
| | Neoplasm Staging | 3 | 2024 | 1397 | 0.260 |
Why?
| | Fatal Outcome | 2 | 2017 | 309 | 0.250 |
Why?
| | Retrospective Studies | 9 | 2025 | 16447 | 0.250 |
Why?
| | Michigan | 1 | 2025 | 132 | 0.230 |
Why?
| | Databases, Factual | 2 | 2022 | 1449 | 0.220 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 35 | 0.220 |
Why?
| | Immunoconjugates | 1 | 2026 | 127 | 0.210 |
Why?
| | Disease Management | 2 | 2018 | 634 | 0.210 |
Why?
| | Methotrexate | 2 | 2023 | 255 | 0.210 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 92 | 0.210 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 20 | 0.210 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2554 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 191 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 82 | 0.200 |
Why?
| | Azacitidine | 1 | 2024 | 149 | 0.200 |
Why?
| | Geriatrics | 1 | 2024 | 96 | 0.190 |
Why?
| | Hospices | 1 | 2024 | 88 | 0.190 |
Why?
| | Melphalan | 1 | 2022 | 40 | 0.190 |
Why?
| | Time-to-Treatment | 1 | 2024 | 224 | 0.190 |
Why?
| | Bortezomib | 1 | 2022 | 52 | 0.190 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 529 | 0.190 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 32 | 0.180 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 261 | 0.180 |
Why?
| | Watchful Waiting | 1 | 2022 | 86 | 0.180 |
Why?
| | Amyloidosis | 1 | 2022 | 47 | 0.180 |
Why?
| | Africa | 1 | 2022 | 113 | 0.180 |
Why?
| | Incidence | 2 | 2026 | 2809 | 0.180 |
Why?
| | Platelet Count | 1 | 2021 | 88 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 100 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 95 | 0.180 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 20 | 0.170 |
Why?
| | Home Care Services | 1 | 2024 | 241 | 0.170 |
Why?
| | Health Occupations | 1 | 2020 | 34 | 0.170 |
Why?
| | United States | 5 | 2026 | 15298 | 0.160 |
Why?
| | Sirolimus | 1 | 2022 | 276 | 0.160 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 326 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 258 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 364 | 0.160 |
Why?
| | Adolescent | 5 | 2026 | 22116 | 0.160 |
Why?
| | Frailty | 1 | 2023 | 177 | 0.160 |
Why?
| | Sulfonamides | 1 | 2024 | 576 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2022 | 206 | 0.160 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 190 | 0.160 |
Why?
| | Child | 4 | 2026 | 22390 | 0.150 |
Why?
| | Survivorship | 1 | 2020 | 51 | 0.150 |
Why?
| | Botulism | 1 | 2019 | 8 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 428 | 0.150 |
Why?
| | Medical Informatics | 1 | 2020 | 99 | 0.150 |
Why?
| | Personal Satisfaction | 1 | 2021 | 215 | 0.150 |
Why?
| | Program Development | 1 | 2021 | 364 | 0.150 |
Why?
| | Heroin Dependence | 1 | 2019 | 33 | 0.150 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5948 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2019 | 311 | 0.140 |
Why?
| | Pandemics | 3 | 2022 | 1655 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 198 | 0.140 |
Why?
| | Risk Factors | 4 | 2024 | 10490 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 388 | 0.140 |
Why?
| | Social Media | 1 | 2020 | 160 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 123 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 855 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 342 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 653 | 0.130 |
Why?
| | Prednisolone | 1 | 2017 | 68 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 132 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 51 | 0.130 |
Why?
| | Program Evaluation | 1 | 2021 | 919 | 0.130 |
Why?
| | Narration | 1 | 2017 | 68 | 0.130 |
Why?
| | Vaccines | 1 | 2022 | 407 | 0.130 |
Why?
| | Research | 1 | 2020 | 434 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 910 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 641 | 0.120 |
Why?
| | Machine Learning | 1 | 2021 | 555 | 0.120 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 680 | 0.120 |
Why?
| | Pilot Projects | 1 | 2021 | 1820 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 226 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1268 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1243 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 458 | 0.110 |
Why?
| | Thalidomide | 2 | 2024 | 43 | 0.100 |
Why?
| | Anxiety | 1 | 2021 | 1078 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 4006 | 0.100 |
Why?
| | Cytokines | 1 | 2021 | 2079 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 1178 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2021 | 1124 | 0.090 |
Why?
| | Age Factors | 1 | 2020 | 3295 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1210 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1983 | 0.090 |
Why?
| | Infant | 1 | 2026 | 9820 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1490 | 0.090 |
Why?
| | Registries | 1 | 2020 | 2205 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2795 | 0.090 |
Why?
| | Colorado | 1 | 2021 | 4599 | 0.080 |
Why?
| | Child, Preschool | 1 | 2026 | 11511 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 1129 | 0.080 |
Why?
| | Recurrence | 2 | 2024 | 1108 | 0.070 |
Why?
| | Antigens, CD20 | 1 | 2025 | 35 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 23 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 38 | 0.050 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 10 | 0.050 |
Why?
| | Lymphoma, T-Cell | 1 | 2024 | 29 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2024 | 76 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 65 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2023 | 39 | 0.050 |
Why?
| | Hydrazines | 1 | 2023 | 36 | 0.050 |
Why?
| | Imides | 1 | 2022 | 11 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 42 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 223 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 132 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5653 | 0.050 |
Why?
| | Biotin | 1 | 2022 | 26 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 167 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 523 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 108 | 0.040 |
Why?
| | Triazoles | 1 | 2023 | 163 | 0.040 |
Why?
| | Education, Premedical | 1 | 2021 | 5 | 0.040 |
Why?
| | Blogging | 1 | 2021 | 6 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2023 | 225 | 0.040 |
Why?
| | Professionalism | 1 | 2021 | 21 | 0.040 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 98 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1050 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 264 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 467 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 254 | 0.040 |
Why?
| | Plasma | 1 | 2022 | 222 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 390 | 0.040 |
Why?
| | Writing | 1 | 2021 | 99 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 414 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 840 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 859 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 429 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 15 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 494 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 51 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 61 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 395 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2019 | 95 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 175 | 0.030 |
Why?
| | Biomedical Research | 1 | 2024 | 684 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 146 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 151 | 0.030 |
Why?
| | Dyspnea | 1 | 2019 | 258 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 309 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3522 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5809 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|